Abstract
The present invention relates to a method for treating diseases associated with type- 1 interferon signaling. Particularly, the present invention is directed to use of specific inhibitors of Voltage-Dependent Anion Channel (VDAC1), such as piperazine- and/or piperidine-derivatives, among others, e.g., peptides and oligonucleotides, for treating an autoimmune disease.
| Original language | English |
|---|---|
| Patent number | WO2020110111 |
| IPC | A61P 37/ 06 A I |
| Priority date | 26/11/18 |
| State | Published - 4 Jun 2020 |